ALK and non-small cell lung carcinoma: These indications included first‐line monotherapy in Stage 3 patients unable to undergo surgical resection, chemoradiation, or with metastatic NSCLC with PD‐L1 expression 1% or greater and no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations.5